India's Ministry of Health and Family Welfare has proposed amendments to the Drugs Rules, 1945, to include Flupentixol, Zopiclone, Gabapentin and Carisoprodol under Schedule H1. Stakeholders may submit objections within 30 days. If finalised, the proposed amendments will take effect within 180 days after publication of the final rules.
In India, lawyers and law firms are not permitted to solicit work and advertise themselves. By clicking on the “I agree” button, you hereby agree and acknowledge that:
The information contained on this website is for general informational purposes only. While Arogya Legal and Compliance Solutions (ALCS) strives to keep the information up to date and accurate, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information, products, services, or related graphics contained on the website.
The content on this website, including articles, videos, news updates, and other materials, is intended for informational purposes only and should not be construed as legal advice. No attorney-client relationship is created by accessing this website, reading its content, or contacting us through the website. For specific legal advice regarding your situation, please consult with a qualified legal professional.
Submitting a contact form, sending an email, or any other form of communication through this website does not establish a professional relationship between you and ALCS. A professional engagement is only formed upon execution of a formal engagement letter or agreement.
Regulatory requirements and legal provisions are subject to change. While we make every effort to ensure that the regulatory information on our website is current, laws, rules, and regulations may be amended or updated by the relevant authorities. Users are advised to verify the latest regulatory requirements with the appropriate government authorities before making any business decisions.
This website may contain links to external websites that are not provided or maintained by ALCS. We do not guarantee the accuracy, relevance, timeliness, or completeness of any information on these external websites and are not responsible for their content or privacy practices.
In no event shall ALCS, its partners, employees, or affiliates be liable for any loss or damage, including without limitation, indirect or consequential loss or damage, arising out of or in connection with the use of this website or reliance on any information provided herein.
If you have any questions about this Disclaimer, please contact us at support@arogyacompliance.com .